WO2021169977A1 - 新型嵌合抗原受体及其用途 - Google Patents
新型嵌合抗原受体及其用途 Download PDFInfo
- Publication number
- WO2021169977A1 WO2021169977A1 PCT/CN2021/077580 CN2021077580W WO2021169977A1 WO 2021169977 A1 WO2021169977 A1 WO 2021169977A1 CN 2021077580 W CN2021077580 W CN 2021077580W WO 2021169977 A1 WO2021169977 A1 WO 2021169977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- cells
- cell
- domain
- chimeric antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 49
- 210000002865 immune cell Anatomy 0.000 claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 46
- 239000000427 antigen Substances 0.000 claims abstract description 45
- 108091007433 antigens Proteins 0.000 claims abstract description 45
- 102000036639 antigens Human genes 0.000 claims abstract description 45
- 230000027455 binding Effects 0.000 claims abstract description 39
- 230000000139 costimulatory effect Effects 0.000 claims abstract description 31
- 230000003834 intracellular effect Effects 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 230000004068 intracellular signaling Effects 0.000 claims abstract description 12
- 230000011664 signaling Effects 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 91
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 82
- 150000007523 nucleic acids Chemical class 0.000 claims description 47
- -1 IL -l Ra Proteins 0.000 claims description 45
- 239000013598 vector Substances 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 230000019491 signal transduction Effects 0.000 claims description 23
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 19
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 13
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 13
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 230000031146 intracellular signal transduction Effects 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 11
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims description 10
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 10
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 10
- 210000000170 cell membrane Anatomy 0.000 claims description 10
- 102100038078 CD276 antigen Human genes 0.000 claims description 9
- 206010039491 Sarcoma Diseases 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 8
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 8
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 210000000581 natural killer T-cell Anatomy 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 7
- 102100021197 G-protein coupled receptor family C group 5 member D Human genes 0.000 claims description 7
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 7
- 101001040713 Homo sapiens G-protein coupled receptor family C group 5 member D Proteins 0.000 claims description 7
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 208000032839 leukemia Diseases 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 102100026094 C-type lectin domain family 12 member A Human genes 0.000 claims description 6
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 6
- 241000702421 Dependoparvovirus Species 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 102100038083 Endosialin Human genes 0.000 claims description 6
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 6
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 6
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 6
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims description 6
- 101000608769 Homo sapiens Galectin-8 Proteins 0.000 claims description 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 6
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims description 6
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims description 6
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 6
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 6
- 102100025390 Integrin beta-2 Human genes 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 6
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 241000714474 Rous sarcoma virus Species 0.000 claims description 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 6
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 6
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 5
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 5
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 5
- 108700012439 CA9 Proteins 0.000 claims description 5
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 5
- 208000017815 Dendritic cell tumor Diseases 0.000 claims description 5
- 101150029707 ERBB2 gene Proteins 0.000 claims description 5
- 101710088083 Glomulin Proteins 0.000 claims description 5
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 5
- 102100032530 Glypican-3 Human genes 0.000 claims description 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 5
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 5
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 5
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 5
- 101001042104 Homo sapiens Inducible T-cell costimulator Proteins 0.000 claims description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 5
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 5
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims description 5
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 5
- 102100021317 Inducible T-cell costimulator Human genes 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 102100034256 Mucin-1 Human genes 0.000 claims description 5
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 108700020467 WT1 Proteins 0.000 claims description 5
- 101150084041 WT1 gene Proteins 0.000 claims description 5
- 210000004443 dendritic cell Anatomy 0.000 claims description 5
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 210000001616 monocyte Anatomy 0.000 claims description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 claims description 5
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 5
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims description 4
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- 230000005945 translocation Effects 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 claims description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 3
- 102100040079 A-kinase anchor protein 4 Human genes 0.000 claims description 3
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 claims description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 3
- 102000017918 ADRB3 Human genes 0.000 claims description 3
- 108060003355 ADRB3 Proteins 0.000 claims description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 3
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 claims description 3
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims description 3
- 102100032187 Androgen receptor Human genes 0.000 claims description 3
- 102100023003 Ankyrin repeat domain-containing protein 30A Human genes 0.000 claims description 3
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims description 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010005949 Bone cancer Diseases 0.000 claims description 3
- 102100037086 Bone marrow stromal antigen 2 Human genes 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 3
- 101710188619 C-type lectin domain family 12 member A Proteins 0.000 claims description 3
- 101710185679 CD276 antigen Proteins 0.000 claims description 3
- 101150013553 CD40 gene Proteins 0.000 claims description 3
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 3
- 102100035793 CD83 antigen Human genes 0.000 claims description 3
- 102100037904 CD9 antigen Human genes 0.000 claims description 3
- 102100029390 CMRF35-like molecule 1 Human genes 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 102000013392 Carboxylesterase Human genes 0.000 claims description 3
- 108010051152 Carboxylesterase Proteins 0.000 claims description 3
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 3
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 3
- 101710178046 Chorismate synthase 1 Proteins 0.000 claims description 3
- 102100038449 Claudin-6 Human genes 0.000 claims description 3
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 108050006400 Cyclin Proteins 0.000 claims description 3
- 102000016736 Cyclin Human genes 0.000 claims description 3
- 101710152695 Cysteine synthase 1 Proteins 0.000 claims description 3
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 3
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 3
- 102000012804 EPCAM Human genes 0.000 claims description 3
- 101150084967 EPCAM gene Proteins 0.000 claims description 3
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 3
- 102100023721 Ephrin-B2 Human genes 0.000 claims description 3
- 108010044090 Ephrin-B2 Proteins 0.000 claims description 3
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 3
- 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 claims description 3
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 3
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 3
- 102000010451 Folate receptor alpha Human genes 0.000 claims description 3
- 108050001931 Folate receptor alpha Proteins 0.000 claims description 3
- 102000010449 Folate receptor beta Human genes 0.000 claims description 3
- 108050001930 Folate receptor beta Proteins 0.000 claims description 3
- 102000003817 Fos-related antigen 1 Human genes 0.000 claims description 3
- 108090000123 Fos-related antigen 1 Proteins 0.000 claims description 3
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 claims description 3
- 102000044445 Galectin-8 Human genes 0.000 claims description 3
- 102100039554 Galectin-8 Human genes 0.000 claims description 3
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 3
- 108010007712 Hepatitis A Virus Cellular Receptor 1 Proteins 0.000 claims description 3
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims description 3
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 3
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 claims description 3
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims description 3
- 101000757191 Homo sapiens Ankyrin repeat domain-containing protein 30A Proteins 0.000 claims description 3
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims description 3
- 101000740785 Homo sapiens Bone marrow stromal antigen 2 Proteins 0.000 claims description 3
- 101000912622 Homo sapiens C-type lectin domain family 12 member A Proteins 0.000 claims description 3
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 claims description 3
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 3
- 101000990055 Homo sapiens CMRF35-like molecule 1 Proteins 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 3
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 3
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 3
- 101000882898 Homo sapiens Claudin-6 Proteins 0.000 claims description 3
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims description 3
- 101000954709 Homo sapiens Doublecortin domain-containing protein 2 Proteins 0.000 claims description 3
- 101001071355 Homo sapiens G-protein coupled receptor 20 Proteins 0.000 claims description 3
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 3
- 101000985516 Homo sapiens Hermansky-Pudlak syndrome 5 protein Proteins 0.000 claims description 3
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims description 3
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 claims description 3
- 101000840267 Homo sapiens Immunoglobulin lambda-like polypeptide 1 Proteins 0.000 claims description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 claims description 3
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 3
- 101000614481 Homo sapiens Kidney-associated antigen 1 Proteins 0.000 claims description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 3
- 101000984197 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily A member 2 Proteins 0.000 claims description 3
- 101001138062 Homo sapiens Leukocyte-associated immunoglobulin-like receptor 1 Proteins 0.000 claims description 3
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 3
- 101001065550 Homo sapiens Lymphocyte antigen 6K Proteins 0.000 claims description 3
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 claims description 3
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims description 3
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 3
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 3
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 3
- 101000721757 Homo sapiens Olfactory receptor 51E2 Proteins 0.000 claims description 3
- 101000613490 Homo sapiens Paired box protein Pax-3 Proteins 0.000 claims description 3
- 101000601724 Homo sapiens Paired box protein Pax-5 Proteins 0.000 claims description 3
- 101000589399 Homo sapiens Pannexin-3 Proteins 0.000 claims description 3
- 101000691463 Homo sapiens Placenta-specific protein 1 Proteins 0.000 claims description 3
- 101001064779 Homo sapiens Plexin domain-containing protein 2 Proteins 0.000 claims description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 claims description 3
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims description 3
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 3
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims description 3
- 101000665137 Homo sapiens Scm-like with four MBT domains protein 1 Proteins 0.000 claims description 3
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 3
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims description 3
- 101000873927 Homo sapiens Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 claims description 3
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims description 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 3
- 101000655352 Homo sapiens Telomerase reverse transcriptase Proteins 0.000 claims description 3
- 101000714168 Homo sapiens Testisin Proteins 0.000 claims description 3
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims description 3
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims description 3
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 claims description 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims description 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims description 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims description 3
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims description 3
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims description 3
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 claims description 3
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 claims description 3
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 3
- 101000808105 Homo sapiens Uroplakin-2 Proteins 0.000 claims description 3
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 3
- 101000814512 Homo sapiens X antigen family member 1 Proteins 0.000 claims description 3
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 3
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 claims description 3
- 102100029616 Immunoglobulin lambda-like polypeptide 1 Human genes 0.000 claims description 3
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 3
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 3
- 102100034872 Kallikrein-4 Human genes 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 102100031413 L-dopachrome tautomerase Human genes 0.000 claims description 3
- 101710093778 L-dopachrome tautomerase Proteins 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 3
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 3
- 102100025586 Leukocyte immunoglobulin-like receptor subfamily A member 2 Human genes 0.000 claims description 3
- 102100020943 Leukocyte-associated immunoglobulin-like receptor 1 Human genes 0.000 claims description 3
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 3
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 3
- 102100032129 Lymphocyte antigen 6K Human genes 0.000 claims description 3
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 claims description 3
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 claims description 3
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 claims description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 3
- 201000003791 MALT lymphoma Diseases 0.000 claims description 3
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims description 3
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 3
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 3
- 108700012912 MYCN Proteins 0.000 claims description 3
- 101150022024 MYCN gene Proteins 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 3
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 3
- 108090000015 Mesothelin Proteins 0.000 claims description 3
- 102000003735 Mesothelin Human genes 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 3
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 claims description 3
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 claims description 3
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 3
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 3
- 206010029260 Neuroblastoma Diseases 0.000 claims description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 3
- 102100025128 Olfactory receptor 51E2 Human genes 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 102100040891 Paired box protein Pax-3 Human genes 0.000 claims description 3
- 102100037504 Paired box protein Pax-5 Human genes 0.000 claims description 3
- 102100032364 Pannexin-3 Human genes 0.000 claims description 3
- 102100026181 Placenta-specific protein 1 Human genes 0.000 claims description 3
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 3
- 102100031889 Plexin domain-containing protein 2 Human genes 0.000 claims description 3
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 3
- 208000007541 Preleukemia Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 claims description 3
- 102100032831 Protein ITPRID2 Human genes 0.000 claims description 3
- 102100037686 Protein SSX2 Human genes 0.000 claims description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 201000000582 Retinoblastoma Diseases 0.000 claims description 3
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 3
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 3
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 claims description 3
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 3
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 3
- 102100035748 Squamous cell carcinoma antigen recognized by T-cells 3 Human genes 0.000 claims description 3
- 108010002687 Survivin Proteins 0.000 claims description 3
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims description 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims description 3
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 3
- 108010032166 TARP Proteins 0.000 claims description 3
- 108010017842 Telomerase Proteins 0.000 claims description 3
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 3
- 206010057644 Testis cancer Diseases 0.000 claims description 3
- 102100036494 Testisin Human genes 0.000 claims description 3
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 102100029337 Thyrotropin receptor Human genes 0.000 claims description 3
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 claims description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims description 3
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 3
- 102100027009 Toll-like receptor 10 Human genes 0.000 claims description 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims description 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims description 3
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims description 3
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims description 3
- 102100021393 Transcriptional repressor CTCFL Human genes 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 3
- 108060008724 Tyrosinase Proteins 0.000 claims description 3
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 claims description 3
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 102100038851 Uroplakin-2 Human genes 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 241000700618 Vaccinia virus Species 0.000 claims description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 3
- 206010047741 Vulval cancer Diseases 0.000 claims description 3
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 3
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 3
- 102100039490 X antigen family member 1 Human genes 0.000 claims description 3
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 3
- 108010080146 androgen receptors Proteins 0.000 claims description 3
- 210000004507 artificial chromosome Anatomy 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 201000000053 blastoma Diseases 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 201000010918 connective tissue cancer Diseases 0.000 claims description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 3
- 201000008184 embryoma Diseases 0.000 claims description 3
- 201000004101 esophageal cancer Diseases 0.000 claims description 3
- 208000024519 eye neoplasm Diseases 0.000 claims description 3
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims description 3
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 108010024383 kallikrein 4 Proteins 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 3
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims description 3
- 201000008106 ocular cancer Diseases 0.000 claims description 3
- 201000002628 peritoneum cancer Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 101150047061 tag-72 gene Proteins 0.000 claims description 3
- 201000003120 testicular cancer Diseases 0.000 claims description 3
- 201000002510 thyroid cancer Diseases 0.000 claims description 3
- 241001430294 unidentified retrovirus Species 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 201000005102 vulva cancer Diseases 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims description 2
- 108010065524 CD52 Antigen Proteins 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 102100037362 Fibronectin Human genes 0.000 claims description 2
- 108010067306 Fibronectins Proteins 0.000 claims description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 2
- 101710094902 Legumin Proteins 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 241001505332 Polyomavirus sp. Species 0.000 claims description 2
- 230000001413 cellular effect Effects 0.000 claims description 2
- 108700010039 chimeric receptor Proteins 0.000 claims description 2
- NEKNNCABDXGBEN-UHFFFAOYSA-L disodium;4-(4-chloro-2-methylphenoxy)butanoate;4-(2,4-dichlorophenoxy)butanoate Chemical compound [Na+].[Na+].CC1=CC(Cl)=CC=C1OCCCC([O-])=O.[O-]C(=O)CCCOC1=CC=C(Cl)C=C1Cl NEKNNCABDXGBEN-UHFFFAOYSA-L 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 claims 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102000002067 Protein Subunits Human genes 0.000 claims 1
- 108010001267 Protein Subunits Proteins 0.000 claims 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 claims 1
- 102100039094 Tyrosinase Human genes 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 230000002147 killing effect Effects 0.000 description 14
- 230000004048 modification Effects 0.000 description 12
- 238000012986 modification Methods 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 10
- 108090000695 Cytokines Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 230000000735 allogeneic effect Effects 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 239000001506 calcium phosphate Substances 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 102000003675 cytokine receptors Human genes 0.000 description 4
- 108010057085 cytokine receptors Proteins 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 3
- 102000002029 Claudin Human genes 0.000 description 3
- 108050009302 Claudin Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000007983 brain glioma Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012096 transfection reagent Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 2
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 description 2
- 238000011357 CAR T-cell therapy Methods 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000936083 Homo sapiens Baculoviral IAP repeat-containing protein 7 Proteins 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 108010002335 Interleukin-9 Proteins 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102000040856 WT1 Human genes 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006690 co-activation Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 208000016847 malignant urinary system neoplasm Diseases 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 208000007525 plasmablastic lymphoma Diseases 0.000 description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 201000004435 urinary system cancer Diseases 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011523 CAR-T cell immunotherapy Methods 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 101001043810 Macaca fascicularis Interleukin-7 receptor subunit alpha Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108700042076 T-Cell Receptor alpha Genes Proteins 0.000 description 1
- 108700042077 T-Cell Receptor beta Genes Proteins 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- QQINRWTZWGJFDB-YPZZEJLDSA-N actinium-225 Chemical compound [225Ac] QQINRWTZWGJFDB-YPZZEJLDSA-N 0.000 description 1
- 229940125666 actinium-225 Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003911 antiadherent Substances 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- JCXGWMGPZLAOME-OUBTZVSYSA-N bismuth-210 Chemical compound [210Bi] JCXGWMGPZLAOME-OUBTZVSYSA-N 0.000 description 1
- JCXGWMGPZLAOME-RNFDNDRNSA-N bismuth-213 Chemical compound [213Bi] JCXGWMGPZLAOME-RNFDNDRNSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 description 1
- 229940055742 indium-111 Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 102000008640 interleukin-21 receptor activity proteins Human genes 0.000 description 1
- 108040002099 interleukin-21 receptor activity proteins Proteins 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229910052741 iridium Inorganic materials 0.000 description 1
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000012634 optical imaging Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000004986 primary T-cell Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000007048 respiratory system cancer Diseases 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/22—Intracellular domain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to the field of cellular immunotherapy, and in particular to a novel chimeric antigen receptor containing a cytokine receptor universal ⁇ chain (also called ⁇ c chain) or its intracellular region and its use.
- a novel chimeric antigen receptor containing a cytokine receptor universal ⁇ chain also called ⁇ c chain
- CAR-T cell immunotherapy is to genetically modify T cells in vitro so that they can recognize tumor antigens, and after being amplified to a certain number, they are returned to the patient to kill cancer cells, thereby achieving the purpose of treating tumors.
- the intracellular signaling domain of the first-generation CAR only contains the primary signaling domain, such as CD3 ⁇ , so CAR-carrying cells (such as CAR-T cells) have poor activity and short survival time in vivo.
- the second-generation CAR introduces a costimulatory domain, such as CD28 or 4-1BB, so that cells can continue to proliferate and enhance anti-tumor activity.
- the third-generation CAR contains two costimulatory domains (such as CD28+4-1BB), and the fourth-generation CAR adds cytokines or costimulatory ligands to further enhance T cell responses, or adds suicide genes when needed. Make CAR-T cells self-destruct.
- the second-generation CAR structure is still mostly used in clinical research.
- CAR-T cell therapy still has some problems in clinical application. For example, there are a large number of tumor recurrences in the treatment of hematoma, and the response rate in the treatment of solid tumors is not high. These may be caused by the complex tumor microenvironment, CAR -Caused by factors such as T cell exhaustion.
- the present invention provides a novel chimeric antigen receptor comprising an antigen binding domain, a transmembrane domain, a costimulatory domain, an intracellular signaling domain, and an additional signaling domain, wherein the additional The signal transduction region is composed of the ⁇ c chain or its intracellular region.
- the amino acid sequence of the ⁇ c chain is shown in SEQ ID NO: 14; the amino acid sequence of its intracellular region is shown in SEQ ID NO: 16.
- the costimulatory domain, intracellular signal transduction domain, and additional signal transduction region are arranged in order from the closest to the farthest distance from the cell membrane.
- the antigen binding region is selected from scFv, Fab, single domain antibody, nanobody, antigen binding ligand, recombinant fibronectin domain, anticalin and DARPIN.
- the antigen binding region is selected from scFv, Fab, single domain antibody and Nanobody.
- the antigen binding region is selected from monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, murine antibodies, and chimeric antibodies.
- the target bound by the antigen binding region is selected from: TSHR, CD19, CD123, CD22, BAFF-R, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA , GPRC5D, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, Mesothelin, IL-1 Ra, PSCA, PRSS21, VEGFR2, LewisY, CD24 , PDGFR- ⁇ , SSEA-4, CD20, Folate receptor ⁇ , ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Claudin 18.2, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAIX, LMP2, gploo, bcr-abl, tyrosinase, EphA2, Fucosyl GMl
- the target is selected from CD19, CD20, CD22, BAFF-R, CD33, EGFRvIII, BCMA, GPRC5D, PSMA, ROR1, FAP, ERBB2 (Her2/neu), MUC1, EGFR, CAIX, WT1, NY-ESO -1, CD79a, CD79b, GPC3, Claudin 18.2, NKG2D and any combination of them.
- the transmembrane domain is selected from the transmembrane domains of the following proteins: TCR ⁇ chain, TCR ⁇ chain, TCR ⁇ chain, TCR ⁇ chain, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD45, CD4, CD5, CD8 ⁇ , CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.
- the transmembrane domain is selected from the transmembrane domains of CD8 ⁇ , CD4, CD28 and CD278.
- the intracellular signaling domain is selected from the signaling domains of the following proteins: FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD22, CD79a, CD79b, and CD66d.
- the intracellular signaling domain is a signaling domain comprising CD3 ⁇ .
- the costimulatory domain is one or more costimulatory signaling domains selected from the following proteins: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11 , CD2, CD7, CD8, CD18 (LFA-1), CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD270 (HVEM), CD272 (BTLA) , CD276 (B7-H3), CD278 (ICOS), CD357 (GITR), DAP10, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM and ZAP70.
- the costimulatory domain is a costimulatory signal transduction domain of CD27, CD28, CD134, CD137 or CD278.
- the present invention also provides a nucleic acid comprising a sequence encoding the chimeric antigen receptor of the present invention, a vector comprising the nucleic acid, and an immune cell comprising the nucleic acid or the vector.
- the invention provides a nucleic acid comprising a sequence encoding the chimeric antigen receptor of the invention.
- the nucleic acid is DNA or RNA, more preferably mRNA.
- the present invention provides a vector comprising the aforementioned nucleic acid.
- the vector is selected from linear nucleic acid molecules, plasmids, retroviruses, lentiviruses, adenoviruses, vaccinia virus, Rous sarcoma virus (RSV), polyoma virus and adeno-associated virus (AAV), bacteriophages, bacteriophages Granules, cosmids or artificial chromosomes.
- the vector also includes an origin for autonomous replication in immune cells, a selection marker, a restriction enzyme cleavage site, a promoter, a polyadenylic acid tail (polyA), 3'UTR, 5'UTR, enhanced Element, terminator, insulator, operon, selectable marker, reporter gene, targeting sequence and/or protein purification tag.
- the vector is an in vitro transcribed vector.
- the present invention provides an immune cell comprising the nucleic acid or vector of the present invention, which is capable of expressing the chimeric antigen receptor of the present invention.
- the immune cells are selected from T cells, macrophages, dendritic cells, monocytes, NK cells or NKT cells.
- the T cells are CD4+/CD8+ double positive T cells, CD4+ helper T cells, CD8+ T cells, tumor infiltrating cells, memory T cells, naive T cells, ⁇ -T cells or ⁇ -T cells.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the chimeric antigen receptor of the present invention or its encoding nucleic acid, vector or immune cell containing them as defined above, and one or more pharmaceutically acceptable Of excipients.
- the present invention provides a method for treating a subject suffering from cancer, comprising administering to the subject an effective amount of the chimeric antigen receptor, immune cell or drug combination according to the present invention Things.
- the cancer is selected from: blastoma, sarcoma, leukemia, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and CNS cancer, breast cancer, peritoneal cancer, cervical cancer, choriocarcinoma , Colon and rectal cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, glioblastoma (GBM), liver cancer, hepatocellular tumor, intraepithelial tumor, Kidney cancer, laryngeal cancer, leukemia, liver tumor, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, Respiratory system cancer, salivary gland cancer, skin cancer, squamous cell carcinoma, stomach cancer, testi
- the disease that can be treated with the chimeric antigen receptor, nucleic acid, vector, immune cell or pharmaceutical composition of the present invention is selected from: leukemia, lymphoma, multiple myeloma, brain glioma, pancreatic cancer, gastric cancer Wait.
- chimeric antigen receptor refers to an artificially constructed hybrid polypeptide.
- the basic structure of the hybrid polypeptide includes an antigen-binding region (for example, the antigen-binding portion of an antibody), a transmembrane domain, Co-stimulatory domain and intracellular signaling domain.
- CAR can use the antigen-binding properties of monoclonal antibodies to redirect the specificity and reactivity of T cells and other immune cells to selected targets in a non-MHC-restricted manner.
- Non-MHC-restricted antigen recognition gives CAR-expressing T cells the ability to recognize antigens unrelated to antigen processing, thus bypassing the main mechanism of tumor escape.
- the CAR when expressed in T cells, the CAR advantageously does not dimerize with the alpha and beta chains of the endogenous T cell receptor (TCR).
- TCR T cell receptor
- the novel chimeric antigen receptor of the present invention includes, in addition to the basic structures of the antigen binding domain, transmembrane domain, costimulatory domain and intracellular signal transduction domain, it also includes an additional ⁇ c chain or its intracellular region. Signal conduction area.
- antigen binding region refers to any structure or functional variant thereof that can bind to an antigen.
- the antigen binding region can be an antibody structure, including but not limited to monoclonal antibodies, polyclonal antibodies, recombinant antibodies, human antibodies, humanized antibodies, chimeric antibodies and functional fragments thereof.
- the antigen binding region includes but is not limited to Fab, single chain antibody (Single Chain Antibody Fragment, scFv), single domain antibody (Single Domain Antibody, sdAb), Nanobody (Nanobody, Nb), antigen binding ligand, recombinant fiber
- the zonulin domain, anticalin and DARPIN, etc. are preferably selected from Fab, scFv, sdAb and Nanobody.
- the antigen binding region can be monovalent or bivalent, and can be a monospecific, bispecific or multispecific antibody.
- the antigen binding region can also be a specific binding polypeptide or receptor structure of a specific protein, such as PD1, PDL1, PDL2, TGF ⁇ , APRIL, and NKG2D.
- Fab refers to any of the two identical fragments produced by papain cleavage of immunoglobulin molecules, consisting of a complete light chain and a heavy chain N-terminal part connected by disulfide bonds, wherein the heavy chain N-terminal part includes Heavy chain variable region and CH1. Compared with intact IgG, Fab has no Fc fragment, has higher fluidity and tissue penetration, and can bind to antigen monovalently without mediating antibody effects.
- a “single chain antibody” or “scFv” is an antibody in which the variable region of the heavy chain (VH) of the antibody and the variable region of the light chain (VL) are connected by a linker.
- the optimal length and/or amino acid composition of the linker can be selected.
- the length of the linker will significantly affect the folding and interaction of the variable region of scFv. In fact, if a shorter linker (for example, between 5-10 amino acids) is used, intra-chain folding can be prevented.
- a shorter linker for example, between 5-10 amino acids
- intra-chain folding can be prevented.
- the size and composition of the linker see, for example, Hollinger et al., 1993 Proc Natl Acad. Sci. USA 90: 6444-6448; U.S. Patent Application Publication Nos. 2005/0100543, 2005/0175606, 2007/0014794; and PCT Publication Nos. WO2006/020258 and WO2007/024715, the entire contents
- Single domain antibody or “sdAb” refers to an antibody that naturally lacks the light chain.
- the antibody contains only one heavy chain variable region (VHH) and two conventional CH2 and CH3 regions, also known as the “heavy chain”.
- VHH heavy chain variable region
- CH2 and CH3 regions also known as the "heavy chain”.
- Nemobody or “Nb” refers to a separately cloned and expressed VHH structure, which has structural stability and antigen binding activity equivalent to that of the original heavy chain antibody, and is the smallest unit currently known to bind the target antigen .
- the term "functional variant” or “functional fragment” refers to a variant that essentially contains the amino acid sequence of the parent but contains at least one amino acid modification (ie substitution, deletion or insertion) compared to the parent amino acid sequence, provided that all The variant retains the biological activity of the parent amino acid sequence.
- the amino acid modification is preferably a conservative modification.
- conservative modification refers to an amino acid modification that does not significantly affect or change the binding characteristics of an antibody or antibody fragment containing the amino acid sequence. These conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into the chimeric antigen receptor of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are substitutions in which an amino acid residue is replaced by an amino acid residue having a similar side chain.
- Amino acid residue families with similar side chains have been defined in the art, including basic side chains (such as lysine, arginine, histidine), acidic side chains (such as aspartic acid, glutamic acid) ), uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), non-polar side chains (e.g. alanine, valine) Acid, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ⁇ -branched side chains (e.g.
- basic side chains such as lysine, arginine, histidine
- acidic side chains such as aspartic acid, glutamic acid
- uncharged polar side chains e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
- non-polar side chains e
- amino acids involved threonine, valine, isoleucine
- aromatic side chains such as tyrosine, phenylalanine, tryptophan, histidine.
- Conservative modifications can be selected, for example, based on polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or similarity in the amphipathic properties of the residues involved.
- a “functional variant” or “functional fragment” has at least 75%, preferably at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84% of the parent amino acid sequence. %, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity, And retain the biological activity of the parent amino acid, such as binding activity.
- sequence identity refers to the degree to which two (nucleotide or amino acid) sequences have the same residue at the same position in the alignment, and is usually expressed as a percentage. Preferably, identity is determined over the overall length of the sequences being compared. Therefore, two copies with exactly the same sequence have 100% identity.
- Those skilled in the art will recognize that some algorithms can be used to determine sequence identity using standard parameters, such as Blast (Altschul et al. (1997) Nucleic Acids Res. 25: 3389-3402), Blast2 (Altschul et al. (1990) J. Mol. Biol. 215: 403-410), Smith-Waterman (Smith et al. (1981) J. Mol. Biol. 147: 195-197) and ClustalW.
- the antigen binding region of the present invention binds to one or more targets selected from: TSHR, CD19, CD123, CD22, CD30, CD171, CS-1, CLL-1, CD33, EGFRvIII, GD2, GD3, BCMA, Tn Ag, PSMA, ROR1, FLT3, FAP, TAG72, CD38, CD44v6, CEA, EPCAM, B7H3, KIT, IL-13Ra2, mesothelin, IL-1 Ra, PSCA, PRSS21, VEGFR2 LewisY, CD24, PDGFR- ⁇ , SSEA-4, CD20, Folate receptor ⁇ , ERBB2 (Her2/neu), MUC1, EGFR, NCAM, Prostase, PAP, ELF2M, Ephrin B2, IGF-I receptor, CAI
- the target is selected from: CD19, CD20, CD22, BAFF-R, CD33, EGFRvIII, BCMA, GPRC5D, PSMA, ROR1, FAP, ERBB2 (Her2/neu), MUC1, EGFR, CAIX, WT1, NY- ESO-1, CD79a, CD79b, GPC3, Claudin 18.2, NKG2D and any combination thereof.
- the CAR of the present invention can be designed to include an antigen binding region specific for the antigen.
- a CD19 antibody can be used as the antigen binding region of the present invention.
- transmembrane domain refers to a polypeptide that enables chimeric antigen receptors to be expressed on the surface of immune cells (such as lymphocytes, NK cells, or NKT cells), and guides immune cells to respond to target cells. structure.
- the transmembrane domain can be natural or synthetic, and can also be derived from any membrane-bound protein or transmembrane protein. When the chimeric receptor polypeptide binds to the target antigen, the transmembrane domain is capable of signal transduction.
- Transmembrane domains particularly suitable for use in the present invention can be derived from, for example, TCR ⁇ chain, TCR ⁇ chain, TCR ⁇ chain, TCR ⁇ chain, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD3 ⁇ subunit, CD45, CD4, CD5, CD8 ⁇ , CD9, CD16, CD22, CD33, CD28, CD37, CD64, CD80, CD86, CD134, CD137, CD154 and their functional fragments.
- the transmembrane domain may be synthetic and may contain mainly hydrophobic residues such as leucine and valine.
- the transmembrane domain is derived from a human CD8 ⁇ chain, which has at least 70%, preferably at least 80%, of the amino acid sequence shown in SEQ ID NO: 4 or the nucleotide sequence of SEQ ID NO: 3 , More preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
- the chimeric antigen receptor of the present invention may further comprise a hinge region located between the antigen binding region and the transmembrane domain.
- the term "hinge region” generally refers to any oligopeptide or polypeptide that functions to connect the transmembrane domain to the antigen binding region. Specifically, the hinge region is used to provide greater flexibility and accessibility to the antigen binding region.
- the hinge region may contain up to 300 amino acids, preferably 10 to 100 amino acids and most preferably 25 to 50 amino acids.
- the hinge region may be derived in whole or in part from natural molecules, such as in whole or in part from the extracellular region of CD8, CD4 or CD28, or in whole or in part from the constant region of an antibody.
- the hinge region may be a synthetic sequence corresponding to a naturally occurring hinge sequence, or may be a fully synthetic hinge sequence.
- the hinge region comprises the hinge region of CD8 ⁇ chain, Fc ⁇ RIII ⁇ receptor, IgG4 or IgG1, more preferably CD8 ⁇ hinge, which is the same as the amino acid sequence shown in SEQ ID NO: 12 or the same as SEQ ID NO:
- the nucleotide sequence shown in 11 has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
- intracellular signaling domain refers to the portion of a protein that transduces effector function signals and directs the cell to perform a specified function.
- the intracellular signal transduction domain is responsible for the primary signal transmission in the cell after the antigen binding region binds to the antigen, which leads to the activation of immune cells and immune response.
- the intracellular signaling domain is responsible for activating at least one of the normal effector functions of immune cells in which CAR is expressed.
- the effector function of T cells may be cytolytic activity or auxiliary activity, including the secretion of cytokines.
- the intracellular signaling domain contained in the chimeric antigen receptor of the present invention may be the cytoplasmic sequence of the T cell receptor and the co-receptor, which act together to trigger the primary signal after the antigen receptor is bound. Conduction, as well as any derivatives or variants of these sequences and any synthetic sequences with the same or similar functions.
- the intracellular signal transduction domain can contain many immunoreceptor tyrosine activation motifs (Immunoreceptor Tyrosine-based Activation Motifs, ITAM).
- Non-limiting examples of intracellular signaling domains of the present invention include, but are not limited to, those derived from FcR ⁇ , FcR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD22, CD79a, CD79b, and CD66d.
- the signal transduction domain of the CAR of the present invention may include the CD3 ⁇ signal transduction domain, which is in accordance with the amino acid sequence shown in SEQ ID NO: 8 or the nucleus shown in SEQ ID NO: 7
- the nucleotide sequence has at least 70%, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
- the chimeric antigen receptor of the invention comprises one or more costimulatory domains.
- the costimulatory domain may be an intracellular functional signaling domain derived from a costimulatory molecule, which includes the entire intracellular part of the costimulatory molecule, or a functional fragment thereof.
- a "costimulatory molecule” refers to a homologous binding partner that specifically binds to a costimulatory ligand on T cells, thereby mediating a costimulatory response (for example, proliferation) of T cells.
- Co-stimulatory molecules include, but are not limited to, Class 1 MHC molecules, BTLA and Toll ligand receptors.
- Non-limiting examples of costimulatory domains of the present invention include, but are not limited to, costimulatory signaling domains derived from the following proteins: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11 , CD2, CD7, CD8, CD18 (LFA-1), CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD134 (OX40), CD137 (4-1BB), CD270 (HVEM), CD272 (BTLA) , CD276 (B7-H3), CD278 (ICOS), CD357 (GITR), DAP10, LAT, NKG2C, SLP76, PD-1, LIGHT, TRIM and ZAP70.
- costimulatory signaling domains derived from the following proteins: TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11 , CD2, CD7
- the costimulatory domain of the CAR of the present invention is a 4-1BB and/or CD28 fragment, and more preferably has at least 70% of the amino acid sequence shown in SEQ ID NO: 6 or the nucleotide sequence shown in SEQ ID NO: 5 %, preferably at least 80%, more preferably at least 90%, 95%, 97% or 99% or 100% sequence identity.
- the chimeric antigen receptor of the present invention in addition to the costimulatory domain and the intracellular signal transduction domain for signal transduction, also contains at least one additional signal transduction region consisting of a ⁇ c chain Or its intracellular region.
- the intracellular region (that is, the structure for signal transduction) of the chimeric antigen receptor of the present invention is composed of three types of signal transduction: the costimulatory domain, the intracellular signal transduction domain, and the ⁇ c chain or its intracellular region. Structure and composition.
- the chimeric antigen receptor of the present invention does not contain the fourth signal transduction structure, such as the signal transduction regions of other cytokines, such as IL-2Ra, IL2Ra, IL2Rb, IL4Ra, IL7Ra, IL9Ra, IL15Ra, IL21Ra, etc. Inner zone.
- the fourth signal transduction structure such as the signal transduction regions of other cytokines, such as IL-2Ra, IL2Ra, IL2Rb, IL4Ra, IL7Ra, IL9Ra, IL15Ra, IL21Ra, etc. Inner zone.
- ⁇ c chain refers to the ⁇ chain shared by the receptors of cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.
- the ⁇ c chain was initially identified in the IL-2 receptor, and it was later discovered that it is also involved in the composition of receptors such as IL-4, IL-7, IL-9, IL-15, and IL-21, so it is also called the universal ⁇ chain .
- IL-2R ⁇ the IL-2 receptor
- ⁇ chain also called IL-2R ⁇
- ⁇ c chain also called IL-2R ⁇ or IL-2Rg
- the IL-2 receptor comprising all three chains has the highest affinity for IL-2 cytokine.
- the three chains of IL-2 receptor are anchored on the cell membrane, and the biochemical signal is transmitted to the cell through the binding with IL-2.
- the specific components of cytokine receptors such as IL-2R ⁇ , IL-4R ⁇ , IL-7R ⁇ , IL-9R ⁇ , IL-21R, etc., are responsible for binding to JAK1, while the ⁇ c chain is responsible for binding to JAK1.
- cytokine receptors When these cytokine receptors bind to cytokines, three main signal pathways are activated, including MAP kinase, PI3 kinase and JAK-STAT pathway, which in turn regulate the survival and proliferation of T cells and NK cells.
- ⁇ c chain is a glycoprotein with a molecular weight of 64kD, composed of 347 amino acids, including an extracellular region of 232 amino acids, a transmembrane region of 29 amino acids, and an intracellular region of 86 amino acids.
- the intracellular region contains the Src homologous region, which is essential to promote cell growth and IL-2 mediated expression of c-myc, c-fos, c-jun and other genes.
- the ⁇ c chain that can be used in the present invention has at least 70%, preferably at least 80%, more preferably at least the amino acid sequence shown in SEQ ID NO: 14 or the nucleotide sequence shown in SEQ ID NO: 13 90%, 95%, 97% or 99% or 100% sequence identity.
- the ⁇ c chain intracellular region that can be used in the present invention has at least 70%, preferably at least 80%, with the amino acid sequence shown in SEQ ID NO: 16 or the nucleotide sequence shown in SEQ ID NO: 15, More preferred is at least 90%, 95%, 97% or 99% or 100% sequence identity.
- the ⁇ c chain of the present invention is composed of SEQ ID NO: 14, and its intracellular region is composed of SEQ ID NO: 16.
- the CAR of the present invention may also contain a signal peptide so that when it is expressed in a cell, such as a T cell, the nascent protein is directed to the endoplasmic reticulum and then to the cell surface.
- the core of the signal peptide may contain a long stretch of hydrophobic amino acids, which has a tendency to form a single ⁇ -helix.
- At the end of the signal peptide there is usually an amino acid segment that is recognized and cleaved by signal peptidase.
- Signal peptidase can cleave during or after translocation to produce free signal peptide and mature protein. Then, the free signal peptide is digested by a specific protease.
- the signal peptides that can be used in the present invention are well known to those skilled in the art, such as signal peptides derived from CD8 ⁇ , IgG1, GM-CSFR ⁇ , and the like.
- the chimeric antigen receptor of the present invention includes a CD8 ⁇ transmembrane domain, a 4-1BB costimulatory domain, a CD3 ⁇ signaling domain, and a ⁇ c chain or its intracellular region. More preferably, the chimeric antigen receptor further comprises a CD8 ⁇ signal peptide, a CD8 ⁇ hinge region and/or a CD28 costimulatory domain.
- the costimulatory domain, intracellular signal transduction domain and additional signal transduction domain are arranged in order from the closest to the farthest distance from the cell membrane, that is, the co-stimulatory domain, the intracellular signal transduction domain and the additional signal transduction region
- the stimulus domain is closest to the cell membrane, and the additional signal transduction zone is the farthest from the cell membrane.
- the present invention also provides a nucleic acid comprising a sequence encoding the chimeric antigen receptor of the present invention.
- nucleic acid includes sequences of ribonucleotides and deoxyribonucleotides, such as modified or unmodified RNA or DNA, each of which is linear or circular in single-stranded and/or double-stranded form , Or their mixtures (including hybrid molecules). Therefore, the nucleic acid according to the present invention includes DNA (such as dsDNA, ssDNA, cDNA), RNA (such as dsRNA, ssRNA, mRNA, ivtRNA), combinations or derivatives thereof (such as PNA). Preferably, the nucleic acid is DNA or RNA, more preferably mRNA.
- Nucleic acids may contain conventional phosphodiester bonds or unconventional bonds (such as amide bonds, such as those found in peptide nucleic acids (PNA)).
- the nucleic acid of the present invention may also contain one or more modified bases, such as, for example, trityl bases and unusual bases (such as inosine). Other modifications are also conceivable, including chemical, enzymatic or metabolic modifications, as long as the multi-chain CAR of the present invention can be expressed from polynucleotides.
- the nucleic acid can be provided in an isolated form.
- the nucleic acid may also include regulatory sequences, such as transcription control elements (including promoters, enhancers, operators, repressors, and transcription termination signals), ribosome binding sites, introns, and the like.
- the nucleic acid sequence of the present invention can be codon-optimized for optimal expression in desired host cells (eg, immune cells); or for expression in bacteria, yeast, or insect cells.
- Codon optimization refers to the replacement of codons that are generally rare in the highly expressed genes of a given species in the target sequence with codons that are generally common in the highly expressed genes of such species, and the codons before and after the replacement Code the same amino acid. Therefore, the choice of the best codon depends on the codon usage preference of the host genome.
- the present invention also provides a vector comprising one or more nucleic acids as described in the present invention.
- vector is a nucleic acid molecule used as a vehicle for transferring (exogenous) genetic material into a host cell, where the nucleic acid molecule can be replicated and/or expressed, for example.
- Targeting vector is a medium that delivers an isolated nucleic acid to the inside of a cell by, for example, homologous recombination or using a hybrid recombinase that specifically targets the sequence at the site.
- An “expression vector” is a vector used for the transcription of heterologous nucleic acid sequences (such as those encoding the chimeric antigen receptor polypeptide of the present invention) in a suitable host cell and the translation of their mRNA. Suitable vectors that can be used in the present invention are known in the art, and many are commercially available.
- the vector of the present invention includes, but is not limited to, linear nucleic acid molecules (e.g.
- DNA or RNA DNA or RNA
- plasmids viruses
- viruses e.g. retrovirus, lentivirus, adenovirus, vaccinia virus, Rous sarcoma virus (RSV, multiple Oncovirus and adeno-associated virus (AAV), etc.
- phage phagemid
- cosmid and artificial chromosome including BAC and YAC
- the vector itself is usually a nucleotide sequence, usually a DNA sequence containing an insert (transgene) And the larger sequence as the "backbone" of the vector.
- the engineered vector usually also contains a starting point for autonomous replication in the host cell (if stable expression of the polynucleotide is required), a selection marker and a restriction enzyme cleavage site (such as a multiple cloning site) , MCS).
- the vector may additionally include a promoter, polyadenylic acid tail (polyA), 3'UTR, enhancer, terminator, insulator, operon, selectable marker, reporter gene, targeting sequence and/or protein purification Elements such as tags, etc.
- the vector is an in vitro transcribed vector.
- the present invention provides engineered immune cells, which comprise chimeric antigen receptors or nucleic acid encoding them.
- the term "immune cell” refers to any cell of the immune system that has one or more effector functions (eg, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and/or CDC).
- the immune cells may be T cells, macrophages, dendritic cells, monocytes, NK cells and/or NKT cells.
- the immune cells are T cells.
- the T cell may be any T cell, such as a T cell cultured in vitro, such as a primary T cell, or a T cell derived from a T cell line cultured in vitro, such as Jurkat, SupT1, etc., or a T cell obtained from a subject.
- T cells can be obtained from a variety of sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from the site of infection, ascites, pleural effusion, spleen tissue, and tumors. T cells can also be concentrated or purified.
- T cells can be any type of T cells and can be at any stage of development, including but not limited to CD4+/CD8+ double positive T cells, CD4+ helper T cells (such as Th1 and Th2 cells), CD8+ T cells (such as cytotoxicity) T cells), tumor infiltrating cells, memory T cells, naive T cells, ⁇ -T cells, ⁇ -T cells, etc.
- the immune cells are human T cells.
- Various techniques known to those skilled in the art, such as Ficoll isolation can be used to obtain T cells from the blood of the subject.
- immune cells are engineered to express chimeric antigen receptor polypeptides.
- the nucleic acid sequence encoding the chimeric antigen receptor polypeptide can be introduced into immune cells by conventional methods known in the art (such as by transduction, transfection, transformation, etc.) to express the chimeric antigen receptor polypeptide of the present invention.
- Transfection is the process of introducing nucleic acid molecules or polynucleotides (including vectors) into target cells.
- RNA transfection the process of introducing RNA (such as in vitro transcribed RNA, ivtRNA) into host cells.
- the term is mainly used for non-viral methods in eukaryotic cells.
- transduction is generally used to describe virus-mediated transfer of nucleic acid molecules or polynucleotides.
- Transfection of animal cells usually involves opening transient holes or "holes" in the cell membrane to allow uptake of material. Transfection can be performed using calcium phosphate, by electroporation, by cell extrusion, or by mixing cationic lipids with materials to produce liposomes that fuse with cell membranes and deposit their cargoes inside.
- Exemplary techniques for transfecting eukaryotic host cells include lipid vesicle-mediated uptake, heat shock-mediated uptake, calcium phosphate-mediated transfection (calcium phosphate/DNA co-precipitation), microinjection, and electroporation. perforation.
- transformation is used to describe the non-viral transfer of nucleic acid molecules or polynucleotides (including vectors) into bacteria and non-animal eukaryotic cells (including plant cells). Therefore, transformation is a genetic modification of bacteria or non-animal eukaryotic cells, which is produced by the direct uptake of the cell membrane from its surroundings and subsequent incorporation of exogenous genetic material (nucleic acid molecules). Conversion can be achieved by manual means. In order for transformation to occur, the cell or bacteria must be in a competent state. For prokaryotic transformation, techniques can include heat shock-mediated uptake, bacterial protoplast fusion with intact cells, microinjection, and electroporation.
- the immune cell of the present invention further comprises at least one inactivating gene selected from the group consisting of CD52, GR, TCR ⁇ , TCR ⁇ , CD3 ⁇ , CD3 ⁇ , CD3 ⁇ , CD247 ⁇ , HLA-I, HLA-II genes , Immune checkpoint genes such as PD1 and CTLA-4. More specifically, at least TCR ⁇ or TCR ⁇ genes in immune cells are inactivated. This inactivation renders the TCR non-functional in the cell. This strategy is particularly useful for avoiding graft-versus-host disease (GvHD).
- GvHD graft-versus-host disease
- DNA fragmentation is mediated by meganuclease, zinc finger nuclease, TALE nuclease, or Cas enzyme in the CRISPR system, thereby inactivating the gene.
- the present invention also provides a pharmaceutical composition comprising the chimeric antigen receptor, nucleic acid, carrier or engineered immune cell of the present invention as an active agent, and one or more pharmaceutically acceptable excipients. Therefore, the present invention also covers the use of the chimeric antigen receptor, nucleic acid, vector or engineered immune cell in the preparation of pharmaceutical compositions or medicines.
- the term "pharmaceutically acceptable excipient” refers to pharmacologically and/or physiologically compatible with the subject and the active ingredient (that is, capable of eliciting the desired therapeutic effect without causing any undesirable effects).
- the carriers and/or excipients for the desired local or systemic effects are well-known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995).
- Examples of pharmaceutically acceptable excipients include, but are not limited to, fillers, binders, disintegrants, coating agents, adsorbents, anti-adherents, glidants, antioxidants, flavoring agents, coloring agents, Sweeteners, solvents, co-solvents, buffers, chelating agents, surfactants, diluents, wetting agents, preservatives, emulsifiers, coating agents, isotonic agents, absorption delaying agents, stabilizers and tonicity regulators . It is known to those skilled in the art to select suitable excipients to prepare the desired pharmaceutical composition of the present invention.
- Exemplary excipients used in the pharmaceutical composition of the present invention include saline, buffered saline, dextrose, and water.
- suitable excipients depends inter alia on the active agent used, the disease to be treated, and the desired dosage form of the pharmaceutical composition.
- composition according to the present invention can be applied to various routes of administration. Usually, administration is accomplished parenterally.
- Parenteral delivery methods include topical, intraarterial, intramuscular, subcutaneous, intramedullary, intrathecal, intraventricular, intravenous, intraperitoneal, intrauterine, intravaginal, sublingual, or intranasal administration.
- the pharmaceutical composition according to the present invention can also be prepared into various forms, such as solid, liquid, gaseous or lyophilized form, especially ointment, cream, transdermal patch, gel, powder, tablet, solution, gas In the form of spray, granule, pill, suspension, emulsion, capsule, syrup, elixir, extract, tincture, or liquid extract extract, or a form particularly suitable for the desired method of administration.
- the processes known in the present invention for the production of drugs may include, for example, conventional mixing, dissolving, granulating, sugar coating, grinding, emulsifying, encapsulating, embedding or freeze-drying processes.
- Pharmaceutical compositions containing immune cells such as those described herein are usually provided in the form of a solution, and preferably contain a pharmaceutically acceptable buffer.
- the pharmaceutical composition according to the present invention can also be administered in combination with one or more other agents suitable for the treatment and/or prevention of the disease to be treated.
- agents suitable for the combination include known anticancer drugs such as cisplatin, maytansine derivatives, rachelmycin, calicheamicin, docetaxel, etoposide , Gemcitabine, ifosfamide, irinotecan, melphalan, mitoxantrone, sorfimer sodium photofrin II, temozolomide, topotecan, trimetreate glucuronate, Austria Auristatin E (auristatin E), vincristine and doxorubicin; peptide cytotoxins, such as ricin, diphtheria toxin, pseudomonas bacterial exotoxin A, DNase and RNase; radionuclides, such as iodine 131, rhenium 186, indium 111, iridium 90, bismuth
- the present invention also provides a method for preparing engineered immune cells, which includes introducing the chimeric antigen receptor of the present invention or its encoding nucleic acid sequence into immune cells, so that the immune cells express the chimeric antigen receptor of the present invention.
- the immune cells are human immune cells, more preferably human T cells, macrophages, dendritic cells, monocytes, NK cells and/or NKT cells.
- nucleic acids or vectors into immune cells and expressing them are known in the art.
- the nucleic acid or vector can be introduced into immune cells by physical methods, such as calcium phosphate precipitation method, lipofection method, particle bombardment method, microinjection method, electroporation method, etc.
- chemical methods can also be used, such as through colloidal dispersion systems such as macromolecular complexes, nanocapsules, microspheres, beads, and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles, and lipids
- the body introduces the nucleic acid or vector.
- biological methods can also be used to introduce nucleic acids or vectors.
- viral vectors especially retroviral vectors
- retroviral vectors have become the most common method for inserting genes into mammalian, such as human cells.
- Other viral vectors can be derived from lentivirus, poxvirus, herpes simplex virus I, adenovirus and adeno-associated virus.
- nucleic acid or vector After the nucleic acid or vector is introduced into the immune cells, those skilled in the art can amplify and activate the obtained immune cells by conventional techniques.
- the present invention also provides a method for treating a subject suffering from cancer, which comprises administering to the subject an effective amount of the immune cell or the pharmaceutical composition of the present invention.
- an effective amount of the immune cells and/or pharmaceutical composition of the present invention is directly administered to the subject.
- the treatment method of the present invention is ex vivo treatment.
- the method includes the following steps: (a) providing a sample of the subject, the sample containing immune cells; (b) introducing the chimeric antigen receptor of the present invention into the immune cells in vitro to obtain modified Immune cells, (c) administering the modified immune cells to a subject in need thereof.
- the immune cells provided in step (a) are selected from T cells, NK cells and/or NKT cells; and the immune cells can be obtained from a sample of a subject (especially a blood sample) by conventional methods known in the art. ).
- other immune cells capable of expressing the chimeric antigen receptor of the present invention and exerting the desired biological effect function as described herein can also be used.
- step (c) can be carried out by introducing the nucleic acid or vector described herein into immune cells via electroporation or by infecting immune cells with a viral vector, the viral vector being the aforementioned lentiviral vector, adenoma Viral vector, adeno-associated virus vector or retroviral vector.
- transfection reagents such as liposomes
- the immune cells are autologous or allogeneic cells, preferably T cells, macrophages, dendritic cells, monocytes, NK cells and/or NKT cells, more preferably T cells, NK cells Cells or NKT cells.
- autologous refers to any material derived from an individual that will later be reintroduced into that same individual.
- allogeneic refers to any material derived from a different animal or a different patient of the same species as the individual into which the material is introduced. When the genes at one or more loci are different, two or more individuals are considered to be allogeneic to each other. In some cases, the genetic differences of allogeneic materials from individual individuals of the same species may be sufficient for antigenic interaction to occur.
- the term "subject" is a mammal.
- the mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects representing animal models of cancer.
- the subject is a human.
- the disease is cancer associated with the expression of the target bound by the antigen binding region.
- the cancer includes, but is not limited to: brain glioma, blastoma, sarcoma, leukemia, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and CNS cancer, breast cancer, peritoneal cancer, cervical cancer , Choriocarcinoma, colon and rectal cancer, connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer (including gastrointestinal cancer), glioblastoma (GBM), Liver cancer, hepatocellular tumor, intraepithelial tumor, kidney cancer, laryngeal cancer, liver tumor, lung cancer (such as small cell lung cancer, non-small cell lung cancer, glandular lung cancer, and squamous lung cancer), lymphoma (including Hodgkin's lymphoma and Non-Hodgkin's lymphoma),
- the disease that can be treated with the engineered immune cell or pharmaceutical composition of the present invention is selected from the group consisting of leukemia, lymphoma, multiple myeloma, brain glioma, pancreatic cancer, gastric cancer and the like.
- the method further comprises administering one or more additional chemotherapeutic agents, biological agents, drugs, or treatments to the subject.
- the chemotherapeutic agent, biological agent, drug or treatment is selected from radiotherapy, surgery, antibody agents and/or small molecules and any combination thereof.
- Figure 1 CAR expression level of CAR-T cells measured by flow cytometry.
- Figure 2 The killing effect of CAR-T cells on target cells. Two-way ANOVA was used for analysis, and T test was used for statistical analysis. * Indicates that the P value is less than 0.05, reaching a significant level.
- Figure 3 The release levels of IL-2 (A) and IFN ⁇ (B) after CAR-T cells were co-cultured with target cells and non-target cells.
- FIG. 5 On day D21, the expansion levels of CD3+ (A), CD8+ (B) and CD4+ (C) T cells in mice.
- Figure 7 The killing effect of CAR-T cells on target cells. Two-way ANOVA was used for analysis, and T test was used for statistical analysis. * Indicates that the P value is less than 0.05, reaching a significant level.
- SEQ ID NO describe SEQ ID NO: 1 The nucleotide sequence of CD19-scFv
- the T cells used in all the examples of the present invention are primary human CD4+CD8+T cells isolated from healthy donors by Ficoll-PaqueTM PREMIUM (GE Healthcare, article number 17-5442-02) using leukocyte separation.
- Nalm6 tumor cells were purchased from Nanjing Jicui Yaokang Biotechnology Co., Ltd.
- CD8 ⁇ signal peptide SEQ ID NO: 9
- anti-CD19scFv SEQ ID NO: 1
- CD8 ⁇ hinge region SEQ ID NO: 11
- CD8 ⁇ transmembrane region SEQ ID NO: 3
- 4-1BB costimulatory domain SEQ ID NO: 5
- CD3 ⁇ intracellular signaling domain SEQ ID NO: 7
- the only difference between the bbzg-CAR plasmid and the bbz-CAR plasmid is that it also includes a gamma chain intracellular region (SEQ ID NO: 15) connected to the CD3 ⁇ intracellular signal transduction domain.
- SEQ ID NO: 15 a gamma chain intracellular region connected to the CD3 ⁇ intracellular signal transduction domain.
- the 4-1BB costimulatory domain, the CD3 ⁇ intracellular signal transduction domain and the ⁇ chain intracellular region are arranged in order from the closest to the farthest distance from the cell membrane.
- Opti-MEM After adding 3ml Opti-MEM (Gibco, article number 31985-070) to the sterile tube to dilute the above plasmid, add the packaging vector psPAX2 (Addgene, Product number 12260) and the envelope vector pMD2.G (Addgene, product number 12259). Then, add 120ul X-treme GENE HP DNA transfection reagent (Roche, catalog number 0636236601), mix immediately, incubate at room temperature for 15 minutes, and then add the plasmid/vector/transfection reagent mixture dropwise to the 293T cell culture flask . The virus was collected at 24 hours and 48 hours, and after combining them, ultracentrifugation (25000 g, 4°C, 2.5 hours) was used to obtain concentrated lentivirus.
- T cells were activated with DynaBeads CD3/CD28CTSTM (Gibco, catalog number 40203D), and cultured at 37°C and 5% CO 2 for 1 day. Then, the concentrated lentivirus was added, and after continuous culture for 3 days, traditional con-CAR T cells targeting CD19 (used as a control) and the bbzg-CAR T cells of the present invention were obtained.
- the bbzg-CAR T cell of the present invention can effectively express scFv, and its expression level is slightly higher than that of the traditional bbz-CAR T cell, indicating that the addition of the ⁇ chain intracellular region will not affect the surface expression of the CAR structure.
- Example 2 The killing effect of CAR T cells on target cells and the release of cytokines
- T cells kill target cells the number of target cells will decrease.
- target cells that can express luciferase the number of target cells decreases, and the secreted luciferase also decreases.
- Luciferase can catalyze the conversion of luciferin to oxidized luciferin, and during this oxidation process, bioluminescence will be produced, and the intensity of this luminescence will depend on the level of luciferase expressed by the target cell. Therefore, the detected fluorescence intensity can reflect the killing ability of T cells to target cells.
- Nalm6 target cells carrying the fluorescein gene were first spread into a 96-well plate at 1 ⁇ 10 4 /well, and then an effective target ratio of 32:1 (ie effector T cells and Target cell ratio) Spread bbzg-CAR T cells, Con-CAR T cells (positive control) and untransfected T cells (negative control) into a 96-well plate for co-cultivation, and use a microplate reader after 16-18 hours Determine the fluorescence value. According to the calculation formula: (target cell fluorescence average value-sample fluorescence average value)/target cell fluorescence average value ⁇ 100%, the killing efficiency is calculated, and the result is shown in FIG. 2.
- the bbzg-CAR T cells of the present invention have a significantly higher killing effect on target cells than traditional bbz-CAR T cells.
- ELISA enzyme-linked immunosorbent assay
- the reaction was allowed to occur in the dark at room temperature for 30 minutes, and then 50 ⁇ L of 1 mol/L H 2 SO 4 was added to each well to stop the reaction. Within 30 minutes of stopping the reaction, use a microplate reader to detect the absorbance at 450 nm, and calculate the cytokine content according to the standard curve (drawn according to the reading and concentration of the standard). The result is shown in Figure 3.
- the release of IFN ⁇ was not detected in the non-target cells 293F, indicating that the killing of bbz-CAR T cells and bbzg-CAR T cells is specific.
- the IL2 release level of bbzg-CAR T cells is significantly lower than that of traditional CAR T cells, but the release level of IFN- ⁇ is significantly higher than that of traditional CAR T cells.
- the cytokine release of the bbzg-CAR T cells of the present invention is comparable to that of traditional CAR-T cells.
- mice Twenty 8-week-old healthy female NCG mice were divided into four groups: PBS group, NT group (negative control), bbz-CART group (positive control) and bbzg-CAR T group.
- PBS group On day 0 (D0), 1 ⁇ 10 6 Nalm6 cells were injected into the tail vein of each mouse.
- D7 Seven days later (D7), PBS solution or 2 ⁇ 10 6 NT cells, con-CAR T cells or bbzg-CAR T cells were injected into the tail vein of each mouse according to the grouping situation. The survival rate and tumor burden of the mice were evaluated weekly.
- the in vivo optical imaging technology of living animals was used to evaluate the changes in tumor burden of each group of mice.
- the tumor burden of mice was detected on D7, D14, D21, D28, D35, D42, D49 and expressed in Photons/s. The results are shown in Figure 4.
- mice in the PBS and NT groups progressed rapidly, reaching the highest value at D21 (and then died).
- the tumor burden decreased rapidly, but gradually rebounded on D28 or D35.
- mice in the bbzg-CAR T group not only decreased their tumor burden rapidly after treatment, but also maintained a low level until D49 without recurrence. This indicates that the bbzg-CAR T cell of the present invention can effectively inhibit tumor growth, and the effect is significantly better than that of the traditional bbz-CAR T cell.
- the inventor also monitored the expansion of T cells in the two groups of mice treated with bbz-CART cells and bbzg-CAR T cells on the 21st day. Specifically, blood was taken from the submandibular vein of the mouse on D21, and Trucount FACS analysis (hCD3, hCD8, hCD4 expression levels) was performed, and the results are shown in FIG. 5.
- T cell expansion was detected in both the bbz-CAR T group and the bbzg-CAR T group.
- the expansion of CD4+ T cells in the two groups was similar, the expansion of CD3+ and CD8+ T cells in the bbzg-CAR group T was significantly higher than that in the bbz-CAR T group. Therefore, although the tumor burden on the 21st day of the two groups was similar ( Figure 4), the bbzg-CAR T group had significantly more T cells proliferated, making it possible to keep the tumor burden at a low level. On the contrary, due to less expansion of T cells and continuous depletion, the tumor burden of the bbz-CAR T group mice rebounded afterwards.
- mice in each group were compared to the survival percentage of mice in each group as of the end of the experiment (ie, 105 days after inoculation with tumor cells Nalm6) ( Figure 6).
- Figure 6 the survival percentage of mice in each group as of the end of the experiment.
- all the mice in the PBS and NT groups died, and only one (20%) of the mice treated with bbz-CAR T cells survived, while the mice treated with bbzg-CAR T cells still survived 60%.
- the bbzg-CAR T cells of the present invention can effectively inhibit tumors and improve the survival rate.
- the bbzg-CAR T cells of the present invention can greatly promote the expansion of T cells due to the introduction of the cytokine receptor universal gamma chain, thereby improving the continuous killing of tumor cells. Effect, improve the tumor suppression effect in the body and increase the survival of mice.
- the ⁇ c chain intracellular region (SEQ ID NO: 65) was inserted between the 4-1BB costimulatory domain and the CD3 ⁇ primary signaling domain of the bbz-CAR plasmid to obtain the bbgz-CAR plasmid, which is similar to the bbzg-CAR plasmid. The only difference lies in the position of the intracellular region of the ⁇ c chain. According to the method of Example 1, bbgz-CAR T cells were prepared.
- the killing effect of CAR-T cells on target cells was detected according to the method described in Example 2, and the results are shown in FIG. 7. It can be seen that the killing effect of bbgz-CAR T cells on target cells is equivalent to that of traditional bbz-CAR T cells, but both are significantly lower than the killing effect of bbzg-CAR T cells. This indicates that the position of the additional signal transduction region (ie, the ⁇ c chain or its intracellular region) in the CAR structure has an important impact on the killing activity of CAR T cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
SEQ ID NO | 描述 |
SEQ ID NO:1 | CD19-scFv的核苷酸序列 |
SEQ ID NO:2 | CD19-scFv的氨基酸序列 |
SEQ ID NO:3 | 跨膜结构域CD8α的核苷酸序列 |
SEQ ID NO:4 | 跨膜结构域CD8α的氨基酸序列 |
SEQ ID NO:5 | 共激活结构域4-1BB的核苷酸序列 |
SEQ ID NO:6 | 共激活结构域4-1BB的氨基酸序列 |
SEQ ID NO:7 | 信号传导结构域CD3ζ的核苷酸序列 |
SEQ ID NO:8 | 信号传导结构域CD3ζ的氨基酸序列 |
SEQ ID NO:9 | 信号肽CD8α的核苷酸序列 |
SEQ ID NO:10 | 信号肽CD8α的氨基酸序列 |
SEQ ID NO:11 | CD8α铰链区的核苷酸序列 |
SEQ ID NO:12 | CD8α铰链区的氨基酸序列 |
SEQ ID NO:13 | γc链的核苷酸序列 |
SEQ ID NO:14 | γc链的氨基酸序列 |
SEQ ID NO:15 | γc链胞内区的核苷酸序列 |
SEQ ID NO:16 | γc链胞内区的氨基酸序列 |
Claims (18)
- 一种嵌合抗原受体,其包含抗原结合区、跨膜结构域、共刺激结构域、胞内信号传导结构域和额外信号传导区,其中所述额外信号传导区由γc链或其胞内区组成。
- 根据权利要求1所述的嵌合抗原受体,其中所述共刺激结构域、胞内信号传导结构域和额外信号传导区按照与细胞膜的距离从近到远依次排列。
- 根据权利要求1或2所述的嵌合抗原受体,其中所述γc链的氨基酸序列如SEQ ID NO:14所示;其胞内区的氨基酸序列如SEQ ID NO:16所示。
- 根据权利要求1所述的嵌合抗原受体,其中所述抗原结合区选自sdAb、纳米抗体、抗原结合配体、重组纤连蛋白结构域、anticalin和DARPIN。
- 根据权利要求1所述的嵌合抗原受体,其中所述抗原结合区选自单克隆抗体、多克隆抗体、重组抗体、人抗体、人源化抗体、鼠源抗体和嵌合抗体。
- 根据权利要求1-3任一项所述的嵌合抗原受体,其中所述抗原结合区结合的靶标选自:TSHR、CD19、CD123、CD22、BAFF-R、CD30、CD171、CS-1、CLL-1、CD33、EGFRvIII、GD2、GD3、BCMA、GPRC5D、Tn Ag、PSMA、ROR1、FLT3、FAP、TAG72、CD38、CD44v6、CEA、EPCAM、B7H3、KIT、IL-13Ra2、间皮素、IL-l lRa、PSCA、PRSS21、VEGFR2、LewisY、CD24、PDGFR-β、SSEA-4、CD20、Folate受体α、ERBB2(Her2/neu)、MUC1、EGFR、NCAM、Claudin18.2、Prostase、PAP、ELF2M、Ephrin B2、IGF-I受体、CAIX、LMP2、gploo、bcr-abl、酪氨酸酶、EphA2、Fucosyl GMl、sLe、GM3、TGS5、HMWMAA、o-乙酰基-GD2、Folate受体β、TEM1/CD248、TEM7R、CLDN6、GPRC5D、CXORF61、CD97、CD 179a、ALK、多聚唾液酸、PLAC1、GloboH、NY-BR-1、UPK2、HAVCR1、ADRB3、PANX3、GPR20、LY6K、OR51E2、TARP、WT1、NY-ESO-1、LAGE-la、MAGE-A1、豆荚蛋白、HPV E6、E7、MAGE Al、ETV6-AML、精子蛋白17、XAGE1、Tie 2、MAD-CT-1、MAD-CT-2、Fos相关抗原1、p53、p53突变体、前列腺特异性蛋白、存活蛋白和端粒酶、PCTA-l/Galectin 8、MelanA/MARTl、Ras突变体、hTERT、肉瘤易位断点、ML-IAP、ERG(TMPRSS2 ETS融合基因)、NA17、PAX3、雄激素受体、Cyclin Bl、MYCN、RhoC、TRP-2、CYP1B 1、BORIS、SART3、PAX5、OY-TES 1、LCK、AKAP-4、SSX2、RAGE-1、人端粒酶逆转录酶、RU1、RU2、肠道羧酸酯酶、mut hsp70-2、CD79a、CD79b、CD72、LAIR1、FCAR、LILRA2、CD300LF、CLEC12A、BST2、EMR2、LY75、GPC3、FCRL5、IGLL1、PD1、PDL1、PDL2、TGFβ、APRIL、NKG2D和它们的任意组合。
- 根据权利要求1-6任一项所述的嵌合抗原受体,其中所述跨膜结构域选自以下蛋白 质的跨膜结构域:TCRα链、TCRβ链、TCRγ链、TCRδ链、CD3ζ亚基、CD3ε亚基、CD3γ亚基、CD3δ亚基、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD28、CD37、CD64、CD80、CD86、CD134、CD137和CD154。
- 根据权利要求1-7任一项所述的嵌合抗原受体,其中所述胞内信号传导结构域选自以下蛋白的信号传导结构域:FcRγ、FcRβ、CD3γ、CD3δ、CD3ε、CD3ζ、CD22、CD79a、CD79b和CD66d。
- 根据权利要求1-8任一项所述的嵌合抗原受体,其中所述嵌合受体多肽包含一个或多个共刺激结构域,其中所述共刺激结构域是选自以下蛋白质的共刺激信号传导结构域:TLR1、TLR2、TLR3、TLR4、TLR5、TLR6、TLR7、TLR8、TLR9、TLR10、CARD11、CD2、CD7、CD8、CD18(LFA-1)、CD27、CD28、CD30、CD40、CD54(ICAM)、CD83、CD134(OX40)、CD137(4-1BB)、CD150(SLAMF1)、CD152(CTLA4)、CD223(LAG3)、CD270(HVEM)、CD272(BTLA)、CD273(PD-L2)、CD274(PD-L1)、CD276(B7-H3)、CD278(ICOS)、CD357(GITR)、DAP10、LAT、NKG2C、SLP76、LIGHT、TRIM以及ZAP70。
- 一种核酸,其包含编码根据权利要求1-9任一项所述的嵌合抗原受体。
- 一种载体,包含根据权利要求10所述的核酸。
- 一种免疫细胞,其包含根据权利要求1-9任一项所述的嵌合抗原受体、根据权利要求10所述的核酸,或根据权利要求11所述的载体。
- 根据权利要求12所述的免疫细胞,其中所述载体是线性核酸分子、质粒、逆转录病毒、慢病毒、腺病毒、牛痘病毒、劳氏肉瘤病毒(RSV)、多瘤病毒和腺相关病毒(AAV)、噬菌体、粘粒或人工染色体。
- 根据权利要求12-13任一项所述的免疫细胞,所述免疫细胞选自T细胞、巨噬细胞、树突状细胞、单核细胞、NK细胞或NKT细胞。
- 根据权利要求14所述的免疫细胞,其中所述免疫细胞是选自以下的T细胞:CD4+/CD8+双阳性T细胞、CD4+辅助T细胞、CD8+T细胞、肿瘤浸润细胞、记忆T细胞、幼稚T细胞、γδ-T细胞和αβ-T细胞。
- 根据权利要求12所述的免疫细胞,所述免疫细胞还包含至少一种选自以下的失活基因:CD52、GR、TCRα、TCRβ、CD3γ、CD3δ、CD3ε、CD247ζ、HLA-I、HLA-II基因、免疫检查点基因如PD1和CTLA-4。
- 一种药物组合物,包含根据权利要求1-9任一项所述的嵌合抗原受体、根据权利要求10所述的核酸、根据权利要求11所述的载体或根据权利要求12-16任一项 所述的免疫细胞,和一种或多种药学上可接受的赋型剂。
- 根据权利要求17所述的药物组合物,所述药物组合物用于治疗选自以下的癌症:胚细胞瘤、肉瘤、白血病、基底细胞癌、胆道癌、膀胱癌、骨癌、脑和CNS癌症、乳腺癌、腹膜癌、宫颈癌、绒毛膜癌、结肠和直肠癌、结缔组织癌症、消化系统的癌症、子宫内膜癌、食管癌、眼癌、头颈癌、胃癌、胶质母细胞瘤(GBM)、肝癌、肝细胞瘤、上皮内肿瘤、肾癌、喉癌、白血病、肝肿瘤、肺癌、淋巴瘤、黑色素瘤、骨髓瘤、神经母细胞瘤、口腔癌、卵巢癌、胰腺癌、前列腺癌、视网膜母细胞瘤、横纹肌肉瘤、直肠癌、呼吸系统的癌症、唾液腺癌、皮肤癌、鳞状细胞癌、胃癌、睾丸癌、甲状腺癌、子宫或子宫内膜癌、泌尿系统的恶性肿瘤、外阴癌以及其它癌和肉瘤、以及B细胞淋巴瘤、套细胞淋巴瘤、AIDS相关淋巴瘤、以及Waldenstrom巨球蛋白血症、慢性淋巴细胞白血病(CLL)、急性淋巴细胞白血病(ALL)、B细胞急性淋巴细胞白血病(B-ALL)、T细胞急性淋巴细胞白血病(T-ALL)、B细胞幼淋巴细胞白血病、母细胞性浆细胞样树突状细胞瘤、伯基特氏淋巴瘤、弥散性大B细胞淋巴瘤、滤泡性淋巴瘤、慢性骨髓性白血病(CML)、恶性淋巴组织增生疾病、MALT淋巴瘤、毛细胞白血病、边缘区淋巴瘤、多发性骨髓瘤、骨髓发育不良、浆母细胞性淋巴瘤、白血病前期、浆细胞样树突状细胞瘤、以及移植后淋巴细胞增生性紊乱(PTLD)。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3169610A CA3169610A1 (en) | 2020-02-28 | 2021-02-24 | Novel chimeric antigen receptor and use thereof |
EP21760732.4A EP4083073A4 (en) | 2020-02-28 | 2021-02-24 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF |
KR1020227032920A KR20220145374A (ko) | 2020-02-28 | 2021-02-24 | 신규 키메라 항원 수용체 및 그 용도 |
JP2022549898A JP7462777B2 (ja) | 2020-02-28 | 2021-02-24 | 新規キメラ抗原受容体とその使用 |
AU2021225890A AU2021225890A1 (en) | 2020-02-28 | 2021-02-24 | Novel chimeric antigen receptor and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010128134.7 | 2020-02-28 | ||
CN202010128134.7A CN111269326A (zh) | 2020-02-28 | 2020-02-28 | 新型嵌合抗原受体及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021169977A1 true WO2021169977A1 (zh) | 2021-09-02 |
Family
ID=70995356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/077580 WO2021169977A1 (zh) | 2020-02-28 | 2021-02-24 | 新型嵌合抗原受体及其用途 |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP4083073A4 (zh) |
JP (1) | JP7462777B2 (zh) |
KR (1) | KR20220145374A (zh) |
CN (2) | CN111269326A (zh) |
AU (1) | AU2021225890A1 (zh) |
CA (1) | CA3169610A1 (zh) |
WO (1) | WO2021169977A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022166365A1 (zh) * | 2021-02-03 | 2022-08-11 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
CN117402261A (zh) * | 2023-10-17 | 2024-01-16 | 北京景达生物科技有限公司 | 一种基于重组腺病毒的car-nk细胞制备方法及其应用 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111269326A (zh) * | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
CN111808821B (zh) * | 2020-06-24 | 2022-06-14 | 南方医科大学珠江医院 | Flt3-nkg2d双靶点car-t的构建与制备 |
CN113980136B (zh) * | 2020-07-27 | 2023-08-22 | 中国科学院分子细胞科学卓越创新中心 | 一种包含具有Y/F突变的CD3ε胞内区的嵌合抗原受体及其用途 |
CN111875710A (zh) * | 2020-07-31 | 2020-11-03 | 广东昭泰体内生物医药科技有限公司 | 异质性肿瘤治疗用免疫细胞及其应用 |
CN111875712A (zh) * | 2020-07-31 | 2020-11-03 | 广东昭泰体内生物医药科技有限公司 | 一种增强型靶向muc1的嵌合抗原受体及其应用 |
CN114057890A (zh) * | 2020-07-31 | 2022-02-18 | 南京北恒生物科技有限公司 | 新型共刺激结构域及其用途 |
CN111925448B (zh) * | 2020-08-03 | 2022-06-21 | 山东大学 | 在体生成car-巨噬细胞的制备方法及肿瘤免疫治疗中的应用 |
CN111956795B (zh) * | 2020-08-27 | 2023-02-03 | 武汉波睿达生物科技有限公司 | 以cd99为靶点的嵌合抗原受体联合抗肿瘤药物的应用 |
CN112321721B (zh) * | 2020-11-05 | 2021-07-06 | 山东仁济生物科技有限公司 | 一种嵌合抗原受体及其修饰的免疫细胞及该免疫细胞在晚期胰腺癌治疗上的应用 |
CN113527521B (zh) * | 2020-12-14 | 2022-05-31 | 广州百暨基因科技有限公司 | 一种抗b7h3嵌合抗原受体及其应用 |
CN112877365A (zh) * | 2021-01-19 | 2021-06-01 | 因诺伟(北京)生物医疗科技有限公司 | 一种外周血造血干细胞采集物来源的嵌合抗原受体t细胞的制备及应用 |
TW202300644A (zh) * | 2021-02-24 | 2023-01-01 | 中國大陸商杭州啟函生物科技有限公司 | 免疫細胞中的嵌合抗原受體 |
CN112870227B (zh) * | 2021-03-09 | 2023-04-14 | 深圳市体内生物医药科技有限公司 | 一种肝癌治疗药物及其制备方法和应用 |
CN115216449A (zh) * | 2021-04-16 | 2022-10-21 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
CN115232797A (zh) * | 2021-04-23 | 2022-10-25 | 南京北恒生物科技有限公司 | 工程化免疫细胞及其用途 |
CN113461818B (zh) * | 2021-06-30 | 2022-01-21 | 徐州医科大学 | 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法 |
CN113980138B (zh) * | 2021-08-11 | 2023-08-11 | 卡瑞济(北京)生命科技有限公司 | EphA2嵌合抗原受体以及其用途 |
CN114133457B (zh) * | 2021-12-08 | 2022-08-19 | 郑州源创吉因实业有限公司 | 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用 |
CN116286660B (zh) * | 2022-12-08 | 2023-10-03 | 全球细胞控股(广州)有限公司 | 一种ipsc-(car)自然杀伤细胞、制备方法及其在肿瘤治疗中的应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050100543A1 (en) | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
US20050175606A1 (en) | 2001-04-11 | 2005-08-11 | Hua-Liang Huang | Cyclic single-chain trispecific antibody |
WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
US20070014794A1 (en) | 1995-03-01 | 2007-01-18 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
CN108135988A (zh) * | 2015-10-23 | 2018-06-08 | 奥托路斯有限公司 | 受体 |
CN109328074A (zh) * | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
WO2019112899A2 (en) * | 2017-12-08 | 2019-06-13 | Fate Therepeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
CN109880803A (zh) * | 2017-12-06 | 2019-06-14 | 科济生物医药(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
CN110452882A (zh) * | 2010-12-09 | 2019-11-15 | 宾夕法尼亚大学董事会 | 嵌合抗原受体-修饰的t细胞治疗癌症的用途 |
CN110615843A (zh) * | 2018-06-20 | 2019-12-27 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
CN111269326A (zh) * | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201715918D0 (en) * | 2017-09-29 | 2017-11-15 | Tc Biopharm Ltd | Modified CAR-T |
US20210017248A1 (en) * | 2018-03-16 | 2021-01-21 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
KR20230137923A (ko) * | 2021-02-03 | 2023-10-05 | 바이오헝 테라퓨틱스 리미티드 | 신규한 키메라 항원 수용체 및 이의 용도 |
-
2020
- 2020-02-28 CN CN202010128134.7A patent/CN111269326A/zh active Pending
-
2021
- 2021-02-24 CA CA3169610A patent/CA3169610A1/en active Pending
- 2021-02-24 CN CN202110205785.6A patent/CN113321737A/zh active Pending
- 2021-02-24 JP JP2022549898A patent/JP7462777B2/ja active Active
- 2021-02-24 KR KR1020227032920A patent/KR20220145374A/ko unknown
- 2021-02-24 EP EP21760732.4A patent/EP4083073A4/en active Pending
- 2021-02-24 WO PCT/CN2021/077580 patent/WO2021169977A1/zh unknown
- 2021-02-24 AU AU2021225890A patent/AU2021225890A1/en active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070014794A1 (en) | 1995-03-01 | 2007-01-18 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US20050175606A1 (en) | 2001-04-11 | 2005-08-11 | Hua-Liang Huang | Cyclic single-chain trispecific antibody |
US20050100543A1 (en) | 2003-07-01 | 2005-05-12 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
WO2006020258A2 (en) | 2004-07-17 | 2006-02-23 | Imclone Systems Incorporated | Novel tetravalent bispecific antibody |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
CN110452882A (zh) * | 2010-12-09 | 2019-11-15 | 宾夕法尼亚大学董事会 | 嵌合抗原受体-修饰的t细胞治疗癌症的用途 |
CN108135988A (zh) * | 2015-10-23 | 2018-06-08 | 奥托路斯有限公司 | 受体 |
CN109328074A (zh) * | 2016-04-01 | 2019-02-12 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
CN109880803A (zh) * | 2017-12-06 | 2019-06-14 | 科济生物医药(上海)有限公司 | 嵌合蛋白、表达嵌合蛋白的免疫效应细胞及其应用 |
WO2019112899A2 (en) * | 2017-12-08 | 2019-06-13 | Fate Therepeutics, Inc. | IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS |
CN110615843A (zh) * | 2018-06-20 | 2019-12-27 | 上海隆耀生物科技有限公司 | 一种包含第三信号受体的嵌合抗原受体及其应用 |
CN111269326A (zh) * | 2020-02-28 | 2020-06-12 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
Non-Patent Citations (6)
Title |
---|
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
HOLLINGER, PROC NATL ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448 |
See also references of EP4083073A4 |
SMITH ET AL., J. MOL. BIOL., vol. 147, 1981, pages 195 - 197 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022166365A1 (zh) * | 2021-02-03 | 2022-08-11 | 南京北恒生物科技有限公司 | 新型嵌合抗原受体及其用途 |
CN117402261A (zh) * | 2023-10-17 | 2024-01-16 | 北京景达生物科技有限公司 | 一种基于重组腺病毒的car-nk细胞制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
EP4083073A1 (en) | 2022-11-02 |
CA3169610A1 (en) | 2021-09-02 |
KR20220145374A (ko) | 2022-10-28 |
CN111269326A (zh) | 2020-06-12 |
JP7462777B2 (ja) | 2024-04-05 |
AU2021225890A1 (en) | 2022-08-25 |
EP4083073A4 (en) | 2023-07-12 |
CN113321737A (zh) | 2021-08-31 |
JP2023514385A (ja) | 2023-04-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021169977A1 (zh) | 新型嵌合抗原受体及其用途 | |
WO2021147928A1 (zh) | 包含嵌合抗原受体的免疫细胞及其用途 | |
WO2021129559A1 (zh) | T细胞受体融合蛋白及其用途 | |
WO2022033537A1 (zh) | 工程化免疫细胞及其用途 | |
WO2021238877A1 (zh) | 工程化免疫细胞及其用途 | |
WO2021147929A1 (zh) | 多链嵌合抗原受体及其用途 | |
WO2022048523A1 (zh) | 靶向nk激活性受体的嵌合抗原受体 | |
WO2022166365A1 (zh) | 新型嵌合抗原受体及其用途 | |
WO2022218226A1 (zh) | 工程化免疫细胞及其用途 | |
WO2022223049A1 (zh) | 工程化免疫细胞及其用途 | |
US20240009308A1 (en) | Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof | |
US20230270858A1 (en) | Novel co-stimulatory domain and use thereof | |
WO2023016284A1 (zh) | 工程化免疫细胞及其用途 | |
WO2022267983A1 (zh) | 工程化免疫细胞及其用途 | |
WO2023025009A1 (zh) | 工程化免疫细胞及其用途 | |
WO2023207390A1 (zh) | 一种ciita基因被敲除的工程化免疫细胞及其用途 | |
CN117430712A (zh) | 靶向cxcr6的嵌合抗原受体及其用途 | |
CN117004603A (zh) | 一种cd7基因被敲除的工程化免疫细胞及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21760732 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3169610 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021760732 Country of ref document: EP Effective date: 20220729 |
|
ENP | Entry into the national phase |
Ref document number: 2022549898 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021225890 Country of ref document: AU Date of ref document: 20210224 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20227032920 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |